|Reference : Non Small Cell Lung Carcinoma (Nsclc) at Stage 3. A Fourteen Years Retrospective Study o...|
|Scientific journals : Article|
|Human health sciences : Surgery|
|Non Small Cell Lung Carcinoma (Nsclc) at Stage 3. A Fourteen Years Retrospective Study of 449 Patients. Indications of Surgery in a Multidisciplinary Management|
|RADERMECKER, Marc [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie cardio-vasculaire >]|
|Dekoster, Guy [Université de Liège - ULg > Département des sciences de la santé publique > Département des sciences de la santé publique]|
|Minet, P. [> > > >]|
|Lavigne, Jean-Paul [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie cardio-vasculaire >]|
|Honoré, D. [ > > ]|
|Limet, Raymond [Université de Liège - ULg > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique]|
|Acta Chirurgica Belgica|
|[en] Through a fourteen years retrospective study of all the patients treated at the State University of Liege, we have focused on the survival of 449 patients with, at least, a clinical stage 3 NSCLC disease (NORMS UICC). The whole study was divided in two periods (1972-1978, period 1, and 1979-1985, period 2) because, everything remaining nearly equal as far as the clinical material was concerned, period 2 was characterized by a different therapeutic attitude. Since 1979, the NSCLC stage 3's surgical indications have been widely extended. We have performed surgical resections in patients with NSCLC N2 disease because of positive homolateral mediastinal lymph nodes or with T3 disease. This led the NSCLC stage 3 resection rate to move from 26% in period 1 to 47% in period 2. We report here the effects of such a management on the short and long term survival and the stage 3 NSCLC global prognosis. We noted a modest significant increase in the NSCLC stage 3 global prognosis with a five year survival of 4% and 6% (period 1 and 2 respectively; P = 0.03). The 172 resected patients' outcome did not change (five year survival 11% (P1) and 12% (P2]. Although patients were not randomized, our results suggest that adjuvant therapy should not be added whenever the patient underwent a complete resection. On the other hand, it seems very useful indeed whenever the resection was partial. NSCLC patient at stage 3 who underwent a complete resection achieved a 37% five years survival.|
|Researchers ; Professionals|
There is no file associated with this reference.
All documents in ORBi are protected by a user license.